Todos Medical to Appoint Dr. Paula Trzepacz As Chi
Post# of 1418
(Total Views: 234)
Posted On: 07/12/2019 11:14:24 PM
Todos Medical to Appoint Dr. Paula Trzepacz As Chief Medical Officer And Files New Patent Application
-Joint venture Breakthrough Diagnostics files new patent application covering Alzheimer’s blood diagnostic LymPro Test clinical correlation with amyloid PET imaging
-Preliminary Data on LymPro vs. amyloid PET to be released during AAIC 2019
REHOVOT, Israel, July 12, 2019 (GLOBE NEWSWIRE) --
Todos Medical Ltd. (OTCQB: TOMDF), a clinical-stage in-vitro diagnostics company focused on the development of blood tests for the early detection of cancer and neurodegenerative disorders, such as Alzheimer's disease, today announced the appointment of Dr. Paula Trzepacz as Chief Medical Officer of Breakthrough Diagnostics, Inc. Dr. Trzepacz is a geriatric psychiatrist and neuropsychiatrist with extensive experience in the clinical development of therapeutics and diagnostics for Alzheimer’s disease and other neurocognitive disorders. Dr. Trzepacz is currently serving as Medical Advisor to the Company’s joint venture Breakthrough Diagnostics, Inc. (‘Breakthrough’), an entity that Todos is in the process of acquiring from Amarantus Bioscience Holdings, Inc. (OTCPK: AMBS). Concurrent with this announcement, Breakthrough has filed a new patent application covering the Alzheimer’s blood diagnostic LymPro Test’s correlation to amyloid PET imaging. Preliminary data from an ongoing clinical study at Leipzig University related to the patent filing will be released on July 15th, during AAIC 2019.
"Dr. Trzepacz brings significant expertise to the Company as a pioneer in the clinical development, regulatory process and commercialization of diagnostic tests for neurodegenerative disease, specifically Alzheimer’s disease" said Dr. Herman Weiss, CEO of Todos Medical. "Dr. Trzepacz has extensive experience in dementia and other neurocognitive disorders . Additionally, Dr. Trzepacz served on the global development team for Amyvid, the first FDA approved PET radiotracer indicated for estimation of beta-amyloid plaque density in brains of cognitively impaired persons suspected of having Alzheimer's disease. Dr. Trzepacz’s knowledge of bringing first-of-its-kind diagnostic assays for Alzheimer’s disease to market will make Paula a tremendous asset to our organization.”
"I am delighted to join Todos Medical at a time when the Company is preparing for the introduction of highly specific and sensitive diagnostic assays into the marketplace,” said Dr. Paula Trzepacz, incoming Chief Medical Officer of Breakthrough Diagnostics. “I am looking forward to helping the team at Todos Medical to develop diagnostic blood assays for neurodegenerative diseases, an area that I believe is a key bottleneck in the development of effective therapies for Alzheimer’s."
Dr. Trzepacz was a Senior Medical Fellow in Neurosciences at Eli Lilly and Company (“Lilly”) focused on amyloid assessment in evaluation of cognitive impairment and the scientific exploration of the relationships among a variety of biomarkers across the continuum of Alzheimer’s disease. Her role at Lilly Neurosciences also included registration experience, Phase 2 through Phase 4 drug development programs, medical affairs, medical lead for the Phase 2 mibampator program for agitation and aggression in AD and serving on both the US and global medical teams for the launch of Amyvid, the first FDA approved amyloid PET imaging radiotracer, as a diagnostic adjunct for Alzheimer’s disease in patients with cognitive impairment. She serves on the editorial boards of the Journal of Neuropsychiatry and Clinical Neurosciences, General Hospital Psychiatry, Psychosomatics, and Alzheimer’s and Dementia: Diagnosis, Assessment & Disease Monitoring. She was President of the Academy of Psychosomatic Medicine (APM) from 2004-2005, and President of the American Neuropsychiatric Association (ANPA) from 2009-2011, and is a Fellow of both organizations. Dr. Trzepacz is the recipient of a number of honors and awards, including the 1997 Research Award from APM, and was listed in four editions of Best Doctors in America. Dr. Trzepacz is an international expert in delirium, with extensive clinical and research experience in the assessment and management of neuropsychiatric and geriatric disorders including delirium, dementias, ADHD and traumatic brain injury.
She is a Volunteer Professor of Psychiatry at Indiana University School of Medicine, and an Adjunct Professor of Psychiatry at Tufts University School of Medicine. Dr. Trzepacz has been a principal investigator or research collaborator for numerous international and NIH-funded projects, including a genomics study of post-operative delirium at Duke University
Medical School and research in ICU delirium at Indiana University School of Medicine.
https://investorshangout.com/recentnews/TOMDF#ixzz5tWWw7jSq
Aloha
-Joint venture Breakthrough Diagnostics files new patent application covering Alzheimer’s blood diagnostic LymPro Test clinical correlation with amyloid PET imaging
-Preliminary Data on LymPro vs. amyloid PET to be released during AAIC 2019
REHOVOT, Israel, July 12, 2019 (GLOBE NEWSWIRE) --
Todos Medical Ltd. (OTCQB: TOMDF), a clinical-stage in-vitro diagnostics company focused on the development of blood tests for the early detection of cancer and neurodegenerative disorders, such as Alzheimer's disease, today announced the appointment of Dr. Paula Trzepacz as Chief Medical Officer of Breakthrough Diagnostics, Inc. Dr. Trzepacz is a geriatric psychiatrist and neuropsychiatrist with extensive experience in the clinical development of therapeutics and diagnostics for Alzheimer’s disease and other neurocognitive disorders. Dr. Trzepacz is currently serving as Medical Advisor to the Company’s joint venture Breakthrough Diagnostics, Inc. (‘Breakthrough’), an entity that Todos is in the process of acquiring from Amarantus Bioscience Holdings, Inc. (OTCPK: AMBS). Concurrent with this announcement, Breakthrough has filed a new patent application covering the Alzheimer’s blood diagnostic LymPro Test’s correlation to amyloid PET imaging. Preliminary data from an ongoing clinical study at Leipzig University related to the patent filing will be released on July 15th, during AAIC 2019.
"Dr. Trzepacz brings significant expertise to the Company as a pioneer in the clinical development, regulatory process and commercialization of diagnostic tests for neurodegenerative disease, specifically Alzheimer’s disease" said Dr. Herman Weiss, CEO of Todos Medical. "Dr. Trzepacz has extensive experience in dementia and other neurocognitive disorders . Additionally, Dr. Trzepacz served on the global development team for Amyvid, the first FDA approved PET radiotracer indicated for estimation of beta-amyloid plaque density in brains of cognitively impaired persons suspected of having Alzheimer's disease. Dr. Trzepacz’s knowledge of bringing first-of-its-kind diagnostic assays for Alzheimer’s disease to market will make Paula a tremendous asset to our organization.”
"I am delighted to join Todos Medical at a time when the Company is preparing for the introduction of highly specific and sensitive diagnostic assays into the marketplace,” said Dr. Paula Trzepacz, incoming Chief Medical Officer of Breakthrough Diagnostics. “I am looking forward to helping the team at Todos Medical to develop diagnostic blood assays for neurodegenerative diseases, an area that I believe is a key bottleneck in the development of effective therapies for Alzheimer’s."
Dr. Trzepacz was a Senior Medical Fellow in Neurosciences at Eli Lilly and Company (“Lilly”) focused on amyloid assessment in evaluation of cognitive impairment and the scientific exploration of the relationships among a variety of biomarkers across the continuum of Alzheimer’s disease. Her role at Lilly Neurosciences also included registration experience, Phase 2 through Phase 4 drug development programs, medical affairs, medical lead for the Phase 2 mibampator program for agitation and aggression in AD and serving on both the US and global medical teams for the launch of Amyvid, the first FDA approved amyloid PET imaging radiotracer, as a diagnostic adjunct for Alzheimer’s disease in patients with cognitive impairment. She serves on the editorial boards of the Journal of Neuropsychiatry and Clinical Neurosciences, General Hospital Psychiatry, Psychosomatics, and Alzheimer’s and Dementia: Diagnosis, Assessment & Disease Monitoring. She was President of the Academy of Psychosomatic Medicine (APM) from 2004-2005, and President of the American Neuropsychiatric Association (ANPA) from 2009-2011, and is a Fellow of both organizations. Dr. Trzepacz is the recipient of a number of honors and awards, including the 1997 Research Award from APM, and was listed in four editions of Best Doctors in America. Dr. Trzepacz is an international expert in delirium, with extensive clinical and research experience in the assessment and management of neuropsychiatric and geriatric disorders including delirium, dementias, ADHD and traumatic brain injury.
She is a Volunteer Professor of Psychiatry at Indiana University School of Medicine, and an Adjunct Professor of Psychiatry at Tufts University School of Medicine. Dr. Trzepacz has been a principal investigator or research collaborator for numerous international and NIH-funded projects, including a genomics study of post-operative delirium at Duke University
Medical School and research in ICU delirium at Indiana University School of Medicine.
https://investorshangout.com/recentnews/TOMDF#ixzz5tWWw7jSq
Aloha
(1)
(0)